Published in J Cell Biochem on December 01, 1991
Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol (2002) 2.87
Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci (2009) 2.21
Human mitochondrial DNA is packaged with TFAM. Nucleic Acids Res (2003) 2.01
Directed 3D cell alignment and elongation in microengineered hydrogels. Biomaterials (2010) 1.94
NuMA after 30 years: the matrix revisited. Trends Cell Biol (2010) 1.48
Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. J Virol (1993) 1.19
Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress. Adv Cancer Res (2007) 1.11
High-level transgene expression in plant cells: effects of a strong scaffold attachment region from tobacco. Plant Cell (1996) 1.09
Sequences attaching loops of nuclear and mitochondrial DNA to underlying structures in human cells: the role of transcription units. Nucleic Acids Res (1996) 1.07
Scaffold attachment regions stimulate HSP70.1 expression in mouse preimplantation embryos but not in differentiated tissues. Mol Cell Biol (1994) 0.99
Gene expression in the third dimension: the ECM-nucleus connection. J Mammary Gland Biol Neoplasia (2010) 0.99
Real time imaging of transcriptional activity in live mouse preimplantation embryos using a secreted luciferase. Proc Natl Acad Sci U S A (1995) 0.96
Mapping of genomic DNA loop organization in a 500-kilobase region of the Drosophila X chromosome by the topoisomerase II-mediated DNA loop excision protocol. Mol Cell Biol (1996) 0.96
Tyrosine kinase-dependent release of an adenovirus preterminal protein complex from the nuclear matrix. J Virol (1996) 0.93
Intranuclear anchoring of repetitive DNA sequences: centromeres, telomeres, and ribosomal DNA. J Cell Biol (1999) 0.87
Chromatin without the 30-nm fiber: constrained disorder instead of hierarchical folding. Epigenetics (2014) 0.86
High salt- and SDS-stable DNA binding protein complexes with ATPase and protein kinase activity retained in chromatin-depleted nuclei. Nucleic Acids Res (1995) 0.81
Variations to the nanotube surface for bone regeneration. Int J Biomater (2013) 0.77
The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res (2000) 3.71
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology (1997) 3.61
VCaP, a cell-based model system of human prostate cancer. In Vivo (2001) 3.36
Nuclear protein matrix: association with newly synthesized DNA. Science (1975) 3.27
Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol (1977) 3.26
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst (1998) 2.83
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
DNA packaging and organization in mammalian spermatozoa: comparison with somatic cells. Biol Reprod (1991) 1.99
Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res (1981) 1.99
Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol (2000) 1.97
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 1.69
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol (2001) 1.68
The prostate: an increasing medical problem. Prostate (1990) 1.67
The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem (1980) 1.66
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia (2008) 1.60
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A (1989) 1.55
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res (2000) 1.54
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
Retracted Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res (2000) 1.46
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys (1968) 1.43
The nuclear protein matrix: isolation, structure, and functions. Adv Enzyme Regul (1976) 1.41
Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev (2001) 1.41
Interaction between tetraethylthiuram disulfide and the sulfhydryl groups of D-amino acid oxidase and of hemoglobin. J Biol Chem (1966) 1.38
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology (1998) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol (1988) 1.32
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31
Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. J Cell Biochem (1992) 1.27
Correlation of nuclear morphometry with progression of breast cancer. Cancer (1991) 1.26
Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res (1989) 1.24
Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res (1999) 1.24
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol (1998) 1.22
Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest (1979) 1.20
A sensitive radioassay for sulfhydryl groups with tetraethylthiuram disulfide. J Biol Chem (1966) 1.20
New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology (1999) 1.18
Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis (2000) 1.12
A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res (1993) 1.12
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
Retracted Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology (2001) 1.10
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology (1994) 1.07
Early castration reduces prostatic carcinogenesis in transgenic mice. Urology (1999) 1.07
Decreased galectin-3 expression in prostate cancer. Prostate (2000) 1.07
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol (1999) 1.07
The interaction of natural and synthetic polyanions with mammalian nucleo. I. DNA synthesis. Biochim Biophys Acta (1970) 1.06
Prostate tumor biology and cell kinetics--theory. Urology (1981) 1.05
Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res (1993) 1.05
Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer (1992) 1.05
Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (1982) 1.04
Immunologic implications of vasectomy. II. Serum-mediated immunity. Fertil Steril (1974) 1.04
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer (2006) 1.04
Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol (1978) 1.01
Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol (1999) 1.01
Sperm granulomas: an adverse effect of vasectomy. J Urol (1973) 1.00
Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol (1998) 1.00
Cell structure and DNA organization. Crit Rev Eukaryot Gene Expr (1991) 1.00
Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate (1982) 1.00
Sterility in male animals induced by injection of chemical agents into the vas deferens. Fertil Steril (1973) 0.99
Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res (1998) 0.99
A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol (1982) 0.99
DNA loop domains in mammalian spermatozoa. Chromosoma (1989) 0.99
Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep (1977) 0.99
The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol (1981) 0.98
A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol (1989) 0.98
Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer (1992) 0.98
Effects of neonatal steroids on male sex tissues. Invest Urol (1979) 0.98
Chromium-induced cross-linking of nuclear proteins and DNA. J Biol Chem (1985) 0.97
Studies on crystalline D-amino acid oxidase. V. Characterization of borohydride-reduced enzyme-subtrate intermediate. Synthesis of epsilon-N-(1-carboxyethyl)-L-lysine. J Biol Chem (1967) 0.97
The interaction of natural and synthetic polyanions with mammalian nucleo. II. Nuclear swelling. Biochim Biophys Acta (1970) 0.97
Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res (1987) 0.97
Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst (2000) 0.96
The tissue matrix: cell dynamics and hormone action. Endocr Rev (1990) 0.96
Tumor-associated angiogenesis in prostate cancer. Anticancer Res (1994) 0.96
Experimental models for the study of prostatic adenocarcinoma. J Urol (1977) 0.96
Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res (2000) 0.95
Concepts related to salt resistant estradiol receptors in rat uterine nuclei: nuclear matrix. Biochem Biophys Res Commun (1977) 0.95
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res (1996) 0.94
Studies on crystalline D-amino acid oxidase. II. Isolation of a reduced 14C-labeled substrate-enzyme intermediate after the action of sodium borohydride. J Biol Chem (1965) 0.94
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology (2005) 0.94
Telomerase is activated in the prostate and seminal vesicles of the castrated rat. Endocrinology (1996) 0.93
Biochemical characterization of prostatic nuclei. II. Relationship between DNA synthesis and protein synthesis. Biochim Biophys Acta (1971) 0.93